Table 7 Overall patients’ outcomes.
Characteristics | All patients | Tocilizumab (n = 426, 29.0%) | Non-tocilizumab (n = 1044, 71.0%) | Adjusted OR (95% CI) | P-value |
|---|---|---|---|---|---|
Hospital mortality | 0.75 (0.63–0.89) | < 0.001** | |||
Dead | Overall death 614 (41%) | 157 (36.9%) | 457 (43.8%) | ||
Alive | 269 (63.1%) | 587 (56.2%) | |||
Length of stay in ICU in days | 9 (5–16) | 12 (7–21) | 8 (4–15) | 0.68 (0.57–0.83) | < 0.001*** |
Length of stay in the Hospital in days | 15 (9–124) | 18 (12–30) | 14 (8–23) | 0.72 (0.57–0.91) | 0.003** |
ICU mortality | 3.4 days (2.1–4.8) | < 0.001*** | |||
Dead | 601 (40.9) | 150(35.2.9%) | 452 (43.3%) | ||
Alive | 276 (64.8%) | 592 (56.7%) | |||
Number of patients who required mechanical ventilation | 6 days (1.2–4.0) | < 0.001*** | |||
MV | 778 (52.4%) | 210 (49.3%) | 482 (46.2%) | ||
Didn’t require mechanical ventilation | 216 (50.7%) | 562 (53.8%) | |||
Candidemia | 37 (3.4) | 13 (3.5%) | 24 (3.3%) | – | – |
Bactermia | 263 (24.5) | 82 (21.9) | 181 (26) | – | – |
Complication, bacteremia without candidemia | 225 (21) | 69 (18.4) | 156 (22.4) | – | – |
Complications, positive respiratory culture | – | – | |||
Yes | 32 (7.5%) | 57 (5.5%) | |||
No | 394 (92.5%) | 987 (94.5%) |
